Effect of Consuming a Combination of Probiotic Strains and a Combination of Plant Extracts and a Probiotic Strain on the Production and Nutritional Composition of Breast Milk

Sponsor
Biosearch S.A. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT04639232
Collaborator
(none)
60
1
3
11
5.5

Study Details

Study Description

Brief Summary

The objective of this trial is to evaluate the effect of the consumption of a combination of probiotic strains (Prob-milk) and of a combination of plant extracts plus an inactivated probiotic strain (VoluntasProb) on the production volume and the nutritional composition and the microbiota. of breast milk in lactating women.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Placebo
  • Dietary Supplement: Prob-milk
  • Dietary Supplement: Voluntas-Prob
N/A

Detailed Description

Previous studies have shown the galactogogue effect of fenugreek, fennel, and milk thistle. However, to date no study has considered the evaluation of all three extracts. Additionally, certain probiotic strains of Lactobacillus and Bifidobacterium also appear to increase milk production in animal studies.

The objective of this trial is to evaluate the effect of the consumption of a combination of probiotic strains (Prob-milk) and of a combination of plant extracts plus an inactivated probiotic strain (VoluntasProb) on the production volume and the nutritional composition and the microbiota. of breast milk in lactating women. This is a preliminary study whose purpose is to gather information for future studies.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Other
Official Title:
Multicenter, Randomized, Double-blind Parallel Group Pilot Study to Evaluate the Effect of Consuming a Combination of Probiotic Strains and a Combination of Plant Extracts and a Probiotic Strain on the Production and Nutritional Composition of Breast Milk
Anticipated Study Start Date :
Jan 30, 2021
Anticipated Primary Completion Date :
Aug 31, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Control group

Volunteers will take 6 capsules per day for 28 days a capsule containing maltodextrin.

Dietary Supplement: Placebo
Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.

Experimental: Prob-milk

Volunteers will take 6 capsules per day for 28 days a capsule containing the probiotics combination.

Dietary Supplement: Prob-milk
Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.

Experimental: Voluntas-Prob

Volunteers will take 6 capsules per day for 28 days a capsule containing the combination of plant extracts and the inactivated probiotic strain

Dietary Supplement: Voluntas-Prob
Each participant will consume 6 capsules daily, 2 in every meal, without any restriction in the diet nor in their habits of life.

Outcome Measures

Primary Outcome Measures

  1. Volume of breast milk [28 days]

    The volume of breast milk production will be measured as the difference in weight in grams of the child before and after the first and last feeding of the day, measured on two consecutive days. It should be collected on the first two days before starting treatment and two days in a row separated by one week during treatment.

  2. Microbiota of breast milk [28 days]

    Load of Lactobacillus, Bifidobacterium, Staphylococcus, Streptococcus in breast milk

Secondary Outcome Measures

  1. Nutritional composition of breast milk [28 days]

    Analysis of the content of proteins, fatty acids profile and total fat content, and iron and calcium content in breast milk

  2. Measurement of IL-8 in breast milk [28 days]

    Analysis of the concentration of IL-8 (pg/mL) in breast milk

  3. Measurement of IgA in breast milk [28 days]

    Analysis of the concentration of IgA (ug/mL) in breast milk

  4. Baby feces microbiota [28 days]

    Presence of Lactobacillus spp, Bifidobacterium spp., Streptococcus spp. Staphylococcus spp, Bacteroides spp, E. coli spp, Clostridium spp in baby faeces

  5. Baby's anthropometric measures_weight [28 days]

    Weight (kg) of the baby at baseline, 14 days and 28 days.

  6. Baby's anthropometric measures_height [28 days]

    Height (cm) of the baby at baseline, 14 days and 28 days.

  7. Baby's anthropometric measures_BMI [28 days]

    BMI (kg/m2) of the baby at baseline, 14 days and 28 days.

  8. Data about the intestinal health of the baby_stool frequency [28 days]

    Data about stool frequency (times per day)

  9. Data about the intestinal health of the baby_color of the faeces [28 days]

    Data about color of the feces (yellow, mustard, brown, grey, or green)

  10. Data about the intestinal health of the baby_consistency of the feces [28 days]

    Data about consistency of the feces (hard lumps, sausage with cracks, soft sausage, mushy (like porridge),or watery)

  11. Data about sleep parameters of the baby [28 days]

    Hours of night sleeping per day and hours of total sleeping during the day

  12. Infantile colick symptoms [28 days]

    Presence of infantile colick defined as vigorous and inconsolable crying for more than 3 hours a day for at least 3 weeks

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Lactating women between 18 and 45 years old, who have given birth to a healthy baby at term (born between 37 and 42 weeks).

  2. Who have the perception of having little volume of milk or a nutritional composition of milk that is not adequate for their baby

  3. That they are between week 2 and week 6 of breastfeeding, and that at the time of beginning the study they are not supplementing with formula milk the feeding of their baby.

  4. That they have the firm intention of breastfeeding for 28 more days.

  5. Women who agree to participate and have read, understood and signed the informed consent

Exclusion Criteria:
  1. Suffering from any disease that may hinder or prevent breastfeeding

  2. Being currently consuming or having consumed in the two weeks prior to the study a probiotic or a supplement with plant extracts.

  3. Being consuming any drug that can alter the volume or composition of breast milk.

  4. Have an allergy to any antibiotics or peanuts

  5. Have an allergy to any of the components of the products under study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centro de Salud de Maracena Maracena Granada Spain 18200

Sponsors and Collaborators

  • Biosearch S.A.

Investigators

  • Principal Investigator: Ruth Blanco Rojo, PhD, Biosearch S.A.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Biosearch S.A.
ClinicalTrials.gov Identifier:
NCT04639232
Other Study ID Numbers:
  • P047
First Posted:
Nov 20, 2020
Last Update Posted:
Nov 20, 2020
Last Verified:
Nov 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Biosearch S.A.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 20, 2020